BGU Startup Morphisec Announces Successful $12M Series B Funding Round

BGU startup Morphisec, the leader in Moving Target Defence, announced this week it has raised $12 million in a Series B round of funding. The round features new investor Orange Digital Ventures, the digital investment arm of Orange, as well as existing Morphisec investors Jerusalem Venture Partners, and Deutsche Telekom. Additional investors in Morphisec include La Maison, Portage Partners, OurCrowd, Kodem Growth Partners and Evolution Equity Partners.



Morphisec's patented Moving Target Defence innovation is the foundation of its Endpoint Threat Prevention solution, which quickly and simply prevents advanced threats for customers of all sizes globally. 


Morphisec is the brainchild of BGU researchers Prof. Yuval EloviciDr. Moti Guri and Dudu Mimran of Cyber@BGU. Morphisec was incubated at JVP's Cyber Labs in Beer-Sheva. 


Morphisec's entirely new approach to endpoint protection makes it the only solution that can protect during major operating system patching gaps (like those necessary based on the Spectre and Meltdown exploits) against zero-day attacks (e.g., WannaCry), fileless malware and more, all while providing significant operational and business benefits, including continuity across patch cycles without the need for updates, zero false positives and no performance degradation, support for endpoints and servers in physical, VDI and hybrid environments. 

“Morphisec's success showcases the University's capabilities in bringing excellent academic research to market. We welcome another success from the strong partnership between BGN Technologies and JVP," said Netta Cohen, CEO, BGN Technologies. 

“Morphisec is successfully building a rapidly growing customer portfolio based on its truly unique prevention-based approach. We are thrilled to support the Morphisec team in their acceleration and global reach to fundamentally change cyber protection," said Yann Kandelman, Head of Investment at Orange Digital Ventures. 


“Now is the time to invest in cybersecurity technology that is poised to dramatically hamper attacker's ability to operate and to enable organizations to succeed in eliminating advanced threats," said Yoav Tzruya, JVP General Partner, and Chairman, Board of Directors, Morphisec. “As threats increase in scale and severity, alternative technologies don't fully solve the challenges, while further increasing direct costs and are unable to fend off business continuity issues caused by zero-day threats. Our belief is that Morphisec is well-positioned to become the most critical protective layer in today's rapidly evolving security stack." 


Morphisec's continued growth has been substantial, having achieved over 1000% growth in 2017, with its technology deployed on hundreds of thousands of endpoints. The company announced its Series A funding round in 2015, was named a Gartner Cool Vendor in 2016 and was recognized in 2017 by SE Labs with a 100% efficacy performance rate against every attack (evasive malware and exploits) detonated in the lab. 


“We built Morphisec to become an essential part of every company's security and IT operation, and to defeat attacks that other endpoint technologies cannot," said Ronen Yehoshua, CEO and president, Morphisec. “Our growth has been exponential and this funding will help Morphisec continue on that trajectory. We continue to grow our customer list, our partner ecosystem and our headcount so we can deliver the most groundbreaking technology advancements in a powerful and simple product that prevents advanced threats and exploits like no other." 


More on Morphisec

Morphisec is headquartered in Beer-Sheva, Israel, with U.S. operations in Boston, Mass. The company was incubated at Ben-Gurion University's Cyber Security Research Labs. The company currently has 45 employees globally, is rapidly growing and is hiring across all departments. 


Morphisec offers an entirely new level of innovation to customers with its Endpoint Threat Prevention product, delivering protection against the most advanced cyberattacks. The company's patented Moving Target Defence technology prevents threats others can't, including APTs, zero-days, ransomware, evasive fileless attacks and web-born exploits. This is a truly disruptive technology within the cybersecurity market. 


Morphisec prevents advanced attacks with a powerful yet simple-to-use product that delivers value far beyond security, into IT, with business continuity, cost reduction and OS gap protection leading the list among a growing list of customers. Morphisec provides a crucial, small-footprint memory-defence layer that easily deploys into a company's existing security infrastructure to form a simple, highly effective, cost-efficient prevention stack that is truly disruptive to today's existing cybersecurity model. 


Unlike any other endpoint technology – Morphisec morphs the memory structures of applications, not ever allowing attackers even the opportunity to penetrate endpoints or servers, across on-premise and virtual environments.


Morphisec's Growth Plans

With the recent funding round, Morphisec plans to accelerate its business to deliver innovative cyber security products and services worldwide, focusing on North America, EMEA and APAC. The company has plans to grow its team across Engineering, Sales and Marketing. 


The company also is growing its channel ecosystem of resellers to expand its reach in key geographic locations and across target vertical industries. Just last week, Morphisec announced the addition of HoneyTek and Decision Tree to its stable of North American resellers, a validation of its growth. 


The company plans to announce multiple technology integrations and partnerships shortly also, and will have key personnel presenting at upcoming industry events.